SYF273f83e19ea54360a0ff6e484be870a2Registry ID: 2023-508068-31-00|RecruitingPhase 4
Dupilumab treatment in patients with chronic rhinosinusitis with nasal polyps: the effect on comorbid eosinophilic otitis media
Amsterdam UMC
Loading search results
interventional
N/A
1 country
1
This study aims to determine the effect of dupilumab on ear symptoms and auditory function in chronic rhinosinusitis with nasal polyp and eosinophilic otitis media patients
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 9, 2024
Actual (reported)Change of questionnaire scores between baseline and 6 or 12 months of treatment in CRSwNP+EOM patients
Change of audiometry outcomes between baseline and 6 or 12 months of treatment
Change of questionnaire scores between baseline and 1, 3, 6 and 12 months of treatment
Change of otoscopic findings between baseline and 1, 3, 6 and 12 months of treatment
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Formulated product
Dupixent 300 mg solution for injection in pre-filled pen
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INJECTION
View registry recordThe registry names these ingredients. The formulation’s exact chemical form has not been confirmed.
Dupixent 300 mg solution for injection in pre-filled pen
Named ingredient: dupilumab
View registry recordRegistry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Amsterdam UMC
Amsterdam, 1081 HV, Netherlands
Sietze Reitsma
First Submitted
May 9, 2024
Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Contact the study team to confirm eligibility.